{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:22:58Z","timestamp":1773098578276,"version":"3.50.1"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.phrs.2022.106220","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T22:13:37Z","timestamp":1649456017000},"page":"106220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Overexpressed or hyperactivated Rac1 as a target to treat hepatocellular carcinoma"],"prefix":"10.1016","volume":"179","author":[{"given":"Vincent","family":"Sauzeau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Beignet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Vergoten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Bailly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2022.106220_bib1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1042\/bj20031041","article-title":"Rho GTPases have diverse effects on the organization of the actin filament system","volume":"377","author":"Aspenstr\u00f6m","year":"2004","journal-title":"Biochem J."},{"key":"10.1016\/j.phrs.2022.106220_bib2","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.3390\/ijms19123949","article-title":"Activated Rho GTPases in cancer-the beginning of a new paradigm","volume":"19","author":"Aspenstr\u00f6m","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2022.106220_bib3","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.3390\/cells10112808","article-title":"Rac GTPase signaling in immune-mediated mechanisms of atherosclerosis","volume":"10","author":"Lee","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2022.106220_bib4","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/cells8050396","article-title":"Coordination between Rac1 and Rab proteins: functional implications in health and disease","volume":"8","author":"Margiotta","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2022.106220_bib5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/21541248.2016.1202635","article-title":"GEFs: Dual regulation of Rac1 signaling","volume":"8","author":"MTarei","year":"2017","journal-title":"Small GTPases"},{"key":"10.1016\/j.phrs.2022.106220_bib6","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1042\/BST20200481","article-title":"Mechanisms and consequences of dysregulation of the Tiam family of Rac activators in disease","volume":"48","author":"Maltas","year":"2020","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.phrs.2022.106220_bib7","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3390\/biology10090888","article-title":"VAV proteins as double agents in cancer: oncogenes with tumor suppressor roles","volume":"10","author":"Cuadrado","year":"2021","journal-title":"Biology"},{"key":"10.1016\/j.phrs.2022.106220_bib8","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3390\/biology10090857","article-title":"New functions of vav family proteins in cardiovascular biology, skeletal muscle,and the nervous system","volume":"10","author":"Rodr\u00edguez-Fdez","year":"2021","journal-title":"Biology"},{"key":"10.1016\/j.phrs.2022.106220_bib9","doi-asserted-by":"crossref","first-page":"12596","DOI":"10.3390\/ijms222212596","article-title":"Selectivity determinants of RHO GTPase binding to IQGAPs","volume":"22","author":"Mosaddeghzadeh","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2022.106220_bib10","doi-asserted-by":"crossref","first-page":"9741","DOI":"10.7150\/thno.46913","article-title":", P21-activated kinase 1: emerging biological functions and potential therapeutic targets in Cancer","volume":"10","author":"Yao","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.phrs.2022.106220_bib11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/19420889.2019.1643665","article-title":"CYRI\/ Fam49 proteins represent a new class of Rac1 interactors","volume":"12","author":"Whitelaw","year":"2019","journal-title":"Commun. Integr. Biol."},{"key":"10.1016\/j.phrs.2022.106220_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ceb.2018.04.009","article-title":"Compartmentalisation of RAC1 signalling","volume":"54","author":"Payapilly","year":"2018","journal-title":"Curr. Opin. Cell. Biol."},{"key":"10.1016\/j.phrs.2022.106220_bib13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3390\/cells7120263","article-title":"Post-translational modification and subcellular distribution of Rac1: an update","volume":"7","author":"Abdrabou","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2022.106220_bib14","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.3390\/cells10112984","article-title":"Rho GTPases in skeletal muscle development and homeostasis","volume":"10","author":"Rodr\u00edguez-Fdez","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2022.106220_bib15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/cells8060591","article-title":"Rho GTPases in the physiology and pathophysiology of peripheral sensory neurons","volume":"8","author":"Kalpachidou","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2022.106220_bib16","article-title":"Cortical interneuron development: a role for small Rho GTPases","author":"Kounoupa","year":"2021","journal-title":"Int. J. Dev. Biol."},{"key":"10.1016\/j.phrs.2022.106220_bib17","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.3390\/cells10123395","article-title":"Pathophysiological mechanisms in neurodevelopmental disorders Caused by Rac GTPases dysregulation: what\u2019s behind neuro-RACopathies","volume":"10","author":"Scala","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2022.106220_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/09537104.2018.1475632","article-title":"Platelet Rho GTPase regulation in physiology and disease","volume":"30","author":"Aslan","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.phrs.2022.106220_bib19","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3390\/ijms20040917","article-title":"Small GTPases and their role in vascular disease","volume":"20","author":"Flentje","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2022.106220_bib20","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/thoraxjnl-2020-216271","article-title":"Essential role of smooth muscle Rac1 in severe asthma-associated airway remodelling","volume":"76","author":"Dilasser","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.phrs.2022.106220_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/bph.15805","article-title":"Smooth muscle Rac1 contributes to pulmonary hypertension","author":"Dilasser","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2022.106220_bib22","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3390\/jcm8070965","article-title":"The regulatory role of Rac1, a small molecular weight GTPase, in the development of diabetic retinopathy","volume":"8","author":"Sahajpal","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.phrs.2022.106220_bib23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/cells8050382","article-title":"RAC1 takes the lead in solid tumors","volume":"8","author":"De","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2022.106220_bib24","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.trecan.2020.02.021","article-title":"RAC1 as a therapeutic target in malignant melanoma","volume":"6","author":"Cannon","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.phrs.2022.106220_bib25","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3390\/biom11111554","article-title":"RAC1 activation as a potential therapeutic option in metastatic cutaneous melanoma","volume":"11","author":"Col\u00f3n-Bolea","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.phrs.2022.106220_bib26","doi-asserted-by":"crossref","first-page":"9274016","DOI":"10.1155\/2020\/9274016","article-title":"The role of Rho GTPases in motility and invasion of glioblastoma cells","volume":"2020","author":"Al-Koussa","year":"2020","journal-title":"Anal. Cell. Pathol."},{"key":"10.1016\/j.phrs.2022.106220_bib27","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3390\/cancers12030665","article-title":"Rac1 signaling: from intestinal homeostasis to colorectal cancer metastasis","volume":"12","author":"Kotelevets","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2022.106220_bib28","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3390\/cancers10100358","article-title":"Ovarian tumor microenvironment signaling: convergence on the Rac1 GTPase","volume":"10","author":"Hudson","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2022.106220_bib29","article-title":"Rac1, a potential target for tumor therapy","volume":"11","author":"Liang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2022.106220_bib30","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/leu.2008.71","article-title":"Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis","volume":"22","author":"Thomas","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2022.106220_bib31","first-page":"2021","article-title":"Proapoptotic and antiinvasive activity of Rac1 small molecule inhibitors on malignant glioma cells","volume":"7","author":"Cardama","year":"2014","journal-title":"Oncol. Targets Ther."},{"key":"10.1016\/j.phrs.2022.106220_bib32","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s10555-020-09923-5","article-title":"GTPases in cancer radiotherapy and metastasis","volume":"39","author":"Zeng","year":"2020","journal-title":"Cancer Metastas. Rev."},{"key":"10.1016\/j.phrs.2022.106220_bib33","doi-asserted-by":"crossref","unstructured":"C.W. Zheng, R.J. Zeng, RJ, L.Y. Xu, LY, E.M. Li, EM., Rho GTPases: promising candidates for overcoming chemotherapeutic resistance, Cancer Lett., 475 (2020) 65\u201378.","DOI":"10.1016\/j.canlet.2020.01.018"},{"key":"10.1016\/j.phrs.2022.106220_bib34","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.3390\/cancers12061541","article-title":"Active RAC1 promotes tumorigenic phenotypes and therapy resistance in solid tumors","volume":"12","author":"De","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2022.106220_bib35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/cancers14010103","article-title":"Lifestyleand hepatocellular carcinoma what is the evidence and prevention recommendations","volume":"14","author":"Zelber-Sagi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2022.106220_bib36","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1097\/CM9.0000000000001888","article-title":"Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma","volume":"134","author":"Rios","year":"2021","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.phrs.2022.106220_bib37","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.3390\/cells10113091","article-title":"Treatment for viral hepatitis as secondary prevention for hepatocellular carcinoma","volume":"10","author":"Alqahtani","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2022.106220_bib38","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","article-title":"Global, regional and national burden of primary liver cancer by subtype","volume":"161","author":"Rumgay","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.phrs.2022.106220_bib39","first-page":"19274","article-title":"Hepatocellular carcinoma in 2021: an exhaustive update","volume":"13","author":"Philips","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.phrs.2022.106220_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40364-021-00350-4","article-title":"Recent advances in systemic therapy for hepatocellular carcinoma","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.phrs.2022.106220_bib41","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.2147\/OTT.S268309","article-title":"Clinical evaluation of ramucirumab for the treatment of hepatocellular carcinoma (HCC): place in therapy","volume":"14","author":"Choucair","year":"2021","journal-title":"Oncol. Targets Ther."},{"key":"10.1016\/j.phrs.2022.106220_bib42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2022.106220_bib43","doi-asserted-by":"crossref","DOI":"10.1159\/000521837","article-title":"New frontiers in the medical therapy of hepatocellular carcinoma","author":"Fulgenzi","year":"2022","journal-title":"Chemotherapy"},{"key":"10.1016\/j.phrs.2022.106220_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.771045","article-title":"First-line systemic treatment strategies for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis of Randomized Clinical Trials","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2022.106220_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.747496","article-title":"Infiltrative hepatocellular carcinoma: transcatheter arterial chemoembolization versus hepatic arterial infusion chemotherapy","volume":"11","author":"An","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2022.106220_bib46","article-title":"Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, Randomized, Phase III Trial (FOHAIC-1)","author":"Lyu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2022.106220_bib47","doi-asserted-by":"crossref","unstructured":"J. Zhang, J, X. Zhang, X, H. Mu, H, YG., Yu G, W. Xing, W, L. Wang, L, T. Zhang, T, Surgical conversion for initially unresectable locally advanced hepatocellular carcinomausing a triple combination of angiogenesis inhibitors, Anti-PD-1 antibodies,and hepatic arterial infusion chemotherapy: a retrospective study, Front.Oncol., 11 (2021) 729764.","DOI":"10.3389\/fonc.2021.729764"},{"key":"10.1016\/j.phrs.2022.106220_bib48","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/hep.22240","article-title":"Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway","volume":"47","author":"Liu","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2022.106220_bib49","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbrc.2021.01.017","article-title":"Sleeping beauty insertional mutagenesis screen identifies the pro-metastatic roles of CNPY2 and ACTN2 in hepatocellular carcinoma tumor progression","volume":"541","author":"Lo","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2022.106220_bib50","first-page":"360","article-title":"Rac1 GTPase is activated by hepatitis B virus replication--involvement of HBX","volume":"2008","author":"Tan","year":"1783","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2022.106220_bib51","article-title":"HBX-mediated migration of HBV-replicating HepG2 cells: insights on development of hepatocellular carcinoma","volume":"2009","author":"Feng","year":"2009","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.phrs.2022.106220_bib52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bbrc.2014.10.008","article-title":"RacGTPase-activating protein 1 interacts with hepatitis C virus polymerase NS5B to regulate viral replication","volume":"454","author":"Wu","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2022.106220_bib53","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1158\/1078-0432.CCR-11-0557","article-title":"Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma","volume":"17","author":"Wang","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2022.106220_bib54","first-page":"6815","article-title":"Identification and functional analysis of a core gene module associated with hepatitis C virus-induced human hepatocellular carcinoma progression","volume":"15","author":"Bai","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.phrs.2022.106220_bib55","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1053\/j.gastro.2018.07.010","article-title":"Overexpression of Rac GTPase activating protein 1 contributes to proliferation of cancer cells by reducing hippo signaling to promote cytokinesis","volume":"155","author":"Yang","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2022.106220_bib56","doi-asserted-by":"crossref","first-page":"6901","DOI":"10.1007\/s13277-015-3377-3","article-title":"Upregulated TRIO expression correlates with a malgnant phenotype in human hepatocellular carcinoma","volume":"36","author":"Wang","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.phrs.2022.106220_bib57","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1038\/onc.2011.440","article-title":"Somatic LMCD1 mutations promoted cell migration and tumor metastasis in hepatocellular carcinoma","volume":"31","author":"Chang","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2022.106220_bib58","doi-asserted-by":"crossref","unstructured":"Z. Zhang, Z, X. Liang, X,L. Gao, L, H. Ma, H, X. Liu, X, Y. Pan, Y, W. Yan, W, H. Sha,n H, Z. Wang, Z, Y.H. Chen, YH, C. Ma, C., TIPE1 induces apoptosis by negatively regulating Rac1 activationin hepatocellular carcinoma cells, Oncogene,34 (2015) 2566\u20132574.","DOI":"10.1038\/onc.2014.208"},{"key":"10.1016\/j.phrs.2022.106220_bib59","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3892\/ijo.2014.2451","article-title":"Loss of ARHGDIA expression is associated with poor prognosis in HCC and promotes invasion and metastasis of HCC cells","author":"Liang","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.phrs.2022.106220_bib60","doi-asserted-by":"crossref","first-page":"26971","DOI":"10.1038\/srep26971","article-title":"The NKD1\/Rac1 feedback loop regulates the invasion and migration ability of hepatocarcinoma cells","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2022.106220_bib61","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/hep.23313","article-title":"Liver cancer: EphrinA2 promotes tumorigenicity through Rac1\/Akt\/NF-kappaB signaling pathway","volume":"51","author":"Feng","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2022.106220_bib62","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1600-0463.2011.02855.x","article-title":"Knockdown of BDNF suppressed invasion of HepG2 and HCCLM3 cells, a mechanism associated with inactivation of RhoA or Rac1 and actin skeleton disorganization","volume":"120","author":"Guo","year":"2012","journal-title":"APMIS"},{"key":"10.1016\/j.phrs.2022.106220_bib63","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3892\/or.2012.2216","article-title":"Knockdown of Coronin-1C disrupts Rac1 activation and impairs tumorigenic potential in hepatocellular carcinoma cells","volume":"29","author":"Wang","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.phrs.2022.106220_bib64","doi-asserted-by":"crossref","unstructured":"Y. Zhou, Y, Y. Wang, Y, W. Zhou, W, T. Chen, T, Q. Wu, Q, V.K. Chutturghoon, VK, B. Lin, B, L. Geng, L, Z. Yang, Z, L. Zhou, L, S. Zheng, S, YAP promotes multi-drug resistance and inhibits autophagy-related cell death inhepatocellular carcinoma via the RAC1-ROS-mTOR pathway, Cancer Cell. Int., 19(2019) 179.","DOI":"10.1186\/s12935-019-0898-7"},{"key":"10.1016\/j.phrs.2022.106220_bib65","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.7150\/thno.42596","article-title":"CAMSAP2-mediated noncentrosomal microtubule acetylation drives hepatocellular carcinoma metastasis","volume":"10","author":"Li","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.phrs.2022.106220_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.241","article-title":"IMP2\/p62 induces genomic instability and an aggressive hepatocellular carcinoma phenotype","volume":"6","author":"Kessler","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2022.106220_bib67","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41419-021-04329-9","article-title":"STEAP3 promotes cancer cell proliferation by facilitating nuclear trafficking of EGFR to enhance RAC1-ERK-STAT3 signaling in hepatocellular carcinoma","volume":"12","author":"Wang","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2022.106220_bib68","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/21541248.2020.1728469","article-title":"Targeting effector pathways in RAC1(P29S)-driven malignant melanoma","volume":"12","author":"Uribe-Alvarez","year":"2021","journal-title":"Small GTPases"},{"key":"10.1016\/j.phrs.2022.106220_bib69","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1021\/acs.jpcb.1c00883","article-title":"Mechanistic differences of activation of Rac1(P29S) and Rac1(A159V)","volume":"125","author":"Senyuz","year":"2021","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.phrs.2022.106220_bib70","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.bpj.2021.01.016","article-title":"Oncogenic mutations on Rac1 affect global intrinsic dynamics underlying GTP and PAK1 binding","volume":"120","author":"Acuner","year":"2021","journal-title":"Biophys. J."},{"key":"10.1016\/j.phrs.2022.106220_bib71","doi-asserted-by":"crossref","unstructured":"H.C. Zhou, HC, J.H. Fang, JH, X. Luo, X, L. Zhang, L, J, Yang, J, C. Zhang, C, S.M, Zhuang, SM, Downregulation of microRNA-100 enhances the ICMT-Rac1 signaling and promotes metastasis ofhepatocellular carcinoma cells, Oncotarget., 5 (2014) 12177\u201312188.","DOI":"10.18632\/oncotarget.2601"},{"key":"10.1016\/j.phrs.2022.106220_bib72","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1158\/1535-7163.MCT-18-0955","article-title":"RAC1b overexpression confers resistance to chemotherapy treatment in colorectal cancer","volume":"18","author":"Goka","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2022.106220_bib73","doi-asserted-by":"crossref","unstructured":"R. Zinn, R, H. Otterbein, H, H. Lehnert, H, H. Ungefroren, H., RAC1B: a guardian of the epithelial phenotype and protector against epithelial-mesenchymal transition, Cells, 8(2019) 1569.","DOI":"10.3390\/cells8121569"},{"key":"10.1016\/j.phrs.2022.106220_bib74","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.3390\/cancers12123570","article-title":"RAC1B regulation of TGFB1 reveals an unexpected role of autocrine TGFbeta1 in the suppression of cell motility","volume":"12","author":"Ungefroren","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2022.106220_bib75","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1515\/hsz-2019-0329","article-title":"Different signaling and functionality of Rac1 and Rac1b in the progression of lung adenocarcinoma","volume":"401","author":"Seiz","year":"2020","journal-title":"Biol. Chem."},{"key":"10.1016\/j.phrs.2022.106220_bib76","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1158\/0008-5472.CAN-19-0376","article-title":"DIS3L2 Promotes Progression of Hepatocellular Carcinoma via hnRNP U-Mediated Alternative Splicing","volume":"79","author":"Xing","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2022.106220_bib77","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12964-018-0312-4","article-title":"Blockade of ARHGAP11A reverses malignant progress via inactivating Rac1B in hepatocellular carcinoma","volume":"16","author":"Dai","year":"2018","journal-title":"Cell. Commun. Signal."},{"key":"10.1016\/j.phrs.2022.106220_bib78","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.7150\/thno.42371","article-title":"PEX5, a novel target of microRNA-31-5p, increases radioresistance in hepatocellular carcinoma by activating Wnt\/\u03b2-catenin signaling and homologous recombination","volume":"10","author":"Wen","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.phrs.2022.106220_bib79","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.febslet.2011.03.067","article-title":"MicroRNA-142-3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells","volume":"585","author":"Wu","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.phrs.2022.106220_bib80","doi-asserted-by":"crossref","unstructured":"R.Z. Ran, J. Chen, L.J. Cui, X.L. Lin, M.M. Fan, Z.Z. Cong, H. Zhang, W.F. Tan, G.Q. Zhang, Y.J. Zhang, miR-194 inhibits liver cancer stem cell expansion by regulating RAC1 pathway, Exp. Cell Res. 378 (2019) 66\u201375. Corrigendum in Exp. Cell Res. 395 (2020) 112183.","DOI":"10.1016\/j.yexcr.2020.112183"},{"key":"10.1016\/j.phrs.2022.106220_bib81","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mc.22906","article-title":"miR-365 regulates liver cancer stem cells via RAC1 pathway","volume":"58","author":"Jiang","year":"2019","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.phrs.2022.106220_bib82","first-page":"1163","article-title":"miR-506 regulates cell proliferation and apoptosis by affecting RhoA\/ROCK signaling pathway in hepatocellular carcinoma cells","volume":"12","author":"Zhang","year":"2019","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.phrs.2022.106220_bib83","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/hep.23854","article-title":"MicroRNA-151 and its hosting gene FAK (focal adhesion kinase) regulate tumor cell migration and spreading of hepatocellular carcinoma","volume":"52","author":"Luedde","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2022.106220_bib84","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/gutjnl-2013-306302","article-title":"Endothelial progenitors promote hepatocarcinoma intrahepatic metastasis through monocyte chemotactic protein-1 induction of microRNA-21","volume":"64","author":"Shih","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2022.106220_bib85","first-page":"6126","article-title":"Prognostic value and prospective molecular mechanism of miR-100-5p in hepatocellular carcinoma: A comprehensive study based on 1,258 samples","volume":"18","author":"He","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.phrs.2022.106220_bib86","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nbd.2017.12.006","article-title":"Sodium butyrate triggers a functional elongation of microglial process via Akt-small RhoGTPase activation and HDACs inhibition","volume":"111","author":"Wang","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2022.106220_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2020.108496","article-title":"Butyrate-containing structured lipids inhibit RAC1 and epithelial-to-mesenchymal transition markers: a chemopreventive mechanism against hepatocarcinogenesis","volume":"86","author":"de Conti","year":"2020","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.phrs.2022.106220_bib88","doi-asserted-by":"crossref","unstructured":"H.C. Zhou, HC, C.X. Liu, CX, W.D. Pan, WD, L.R. Shang, LR, J.L. Zheng, JL, B.Y. Huang, BY, J.Y. Chen, JY, L. Zheng, L, J.H. Fang, JH, S.M. Zhuang, SM, Dualand opposing roles of the androgen receptor in VETC-dependent andinvasion-dependent metastasis of hepatocellular carcinoma, J. Hepatol., 75 (2021) 900\u2013911.","DOI":"10.1016\/j.jhep.2021.04.053"},{"key":"10.1016\/j.phrs.2022.106220_bib89","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.3892\/ol.2020.11823","article-title":"Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer","volume":"20","author":"Chen","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.phrs.2022.106220_bib90","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/1535-7163.MCT-20-0695","article-title":"Hormone-dependent prostate cancers are dependent on rac signaling for growth and survival","volume":"20","author":"Goka","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2022.106220_bib91","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/ijms19030804","article-title":"ARHGAP15 in human breast carcinoma: a potent tumor suppressor regulated by androgens","volume":"19","author":"Takagi","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2022.106220_bib92","doi-asserted-by":"crossref","first-page":"915","DOI":"10.18632\/oncotarget.13687","article-title":"Non-toxic dose of liposomal honokiol suppresses metastasis of hepatocellular carcinoma through destabilizing EGFR and inhibiting the downstream pathways","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2022.106220_bib93","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1158\/1535-7163.MCT-06-0149","article-title":"High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis","volume":"5","author":"Yang","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2022.106220_bib94","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2174\/156802606777812095","article-title":"Structure-function based design of small molecule inhibitors targeting Rho family GTPases","volume":"6","author":"Nassar","year":"2006","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.phrs.2022.106220_bib95","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.2174\/1389450115666141027110156","article-title":"Rac-1 as a new therapeutic target in cerebro- and cardio-vascular diseases","volume":"15","author":"Carrizzo","year":"2014","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.phrs.2022.106220_bib96","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1124\/jpet.113.207266","article-title":"NSC23766, a widely used inhibitor of Rac1 activation, additionally acts as a competitive antagonist at muscarinic acetylcholine receptors","volume":"347","author":"Levay","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2022.106220_bib97","doi-asserted-by":"crossref","first-page":"13228","DOI":"10.1074\/jbc.M111.334524","article-title":"Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase","volume":"287","author":"Montalvo-Ortiz","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2022.106220_bib98","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.tranon.2014.07.004","article-title":"The Rac inhibitor EHop-016 inhibits mammary tumor growth and metastasis in a Nude Mouse Model","volume":"7","author":"Castillo-Pichardo","year":"2014","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.phrs.2022.106220_bib99","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jchromb.2014.12.021","article-title":"Pharmacokinetics of Rac inhibitor EHop-016 in mice by ultra-performance liquid chromatography tandem mass spectrometry","volume":"981\u2013982","author":"Humphries-Bickley","year":"2015","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.phrs.2022.106220_bib100","article-title":"In silico identification and characterization of small-molecule inhibitors specific to RhoG\/Rac1 signaling pathway","author":"Dipankar","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.phrs.2022.106220_bib101","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41420-021-00778-5","article-title":"Hypoxia-induced Fascin-1 upregulation is regulated by Akt\/Rac1 axis and enhances malignant properties of liver cancer cells via mediating actin cytoskeleton rearrangement and Hippo\/YAP activation","volume":"7","author":"Pu","year":"2021","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.phrs.2022.106220_bib102","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.bmc.2018.01.003","article-title":"Design, synthesis and biological evaluation of new carbazole derivatives as anti-cancer and anti-migratory agents","volume":"26","author":"Vlaar","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2022.106220_bib103","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.critrevonc.2018.01.012","article-title":"Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics","volume":"124","author":"Cardama","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.phrs.2022.106220_bib104","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3390\/pharmaceutics13071091","article-title":"Timing of novel drug 1A-116 to Circadian rhythms improves therapeutic effects against glioblastoma","volume":"13","author":"Trebucq","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.phrs.2022.106220_bib105","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/cmdc.202000763","article-title":"Development of an improved guanidine-based Rac1 inhibitor with in\u2005vivo activity against non-small cell lung cancer","volume":"16","author":"Ciarlantini","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.phrs.2022.106220_bib106","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/gutjnl-2020-321454","article-title":"Bioinformatic analysis of RHO family of GTPases identifies RAC1 pharmacological inhibition as a new therapeutic strategy for hepatocellular carcinoma","volume":"70","author":"Bayo","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2022.106220_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112806","article-title":"T-lymphoma invasion and metastasis 1 promotes invadopodia formation and is regulated by the PI3K\/Akt signaling pathway in hepatocellular carcinoma","volume":"407","author":"Wang","year":"2021","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.phrs.2022.106220_bib108","doi-asserted-by":"crossref","unstructured":"G.Y. You, GY, J.O. Lee, JO, J.H. Kim, JH, N. Kim, N, S.K. Lee,SK, J.W. Moon, JW, S. Jie, S, H.J. Lee, HJ, S.J. Kim, SJ, PS.H. Park, SH, H.S. Kim,HS., Tiam-1, a GEF for Rac1, plays a critical role in metformin-mediated glucose uptake in C2C12 cells, Cell Signal., 25 (2013) 2558\u20132565.","DOI":"10.1016\/j.cellsig.2013.08.018"},{"key":"10.1016\/j.phrs.2022.106220_bib109","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1159\/000445666","article-title":"NSC23766, a known inhibitor of tiam1-rac1 signaling module, prevents the onset of type 1 diabetes in the NOD Mouse Model","volume":"39","author":"Veluthakal","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.phrs.2022.106220_bib110","first-page":"207","article-title":"Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer","volume":"18","author":"Rosenblatt","year":"2011","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.phrs.2022.106220_bib111","doi-asserted-by":"crossref","first-page":"608","DOI":"10.18632\/oncotarget.520","article-title":"Targeting of Rac GTPases blocks the spread of intact human breast cancer","volume":"3","author":"Katz","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2022.106220_bib112","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.3390\/cancers12061667","article-title":"Rac1 promotes cell motility by controlling cell mechanics in human glioblastoma","volume":"12","author":"Xu","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2022.106220_bib113","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1186\/s12935-021-02183-5","article-title":"Immune classifier-based signatures provide good prognostic stratification and predict the clinical benefits of immune-based therapies for hepatocellular carcinoma","volume":"21","author":"Xue","year":"2021","journal-title":"Cancer Cell Int.,"},{"key":"10.1016\/j.phrs.2022.106220_bib114","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/jth.12861","article-title":"Critical off-target effects of the widely used Rac1 inhibitors NSC23766 and EHT1864 in mouse platelets","volume":"13","author":"D\u00fctting","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.phrs.2022.106220_bib115","unstructured":"Revere Pharmaceuticals, Pipeline."},{"key":"10.1016\/j.phrs.2022.106220_bib116","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1158\/1535-7163.MCT-19-0762","article-title":"Rac signaling drives clear cell renal carcinoma tumor growth by priming the tumor microenvironment for an angiogenic switch","volume":"19","author":"Goka","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2022.106220_bib117","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142182","article-title":"Novel activities of select NSAID R-enantiomers against Rac1 and Cdc42 GTPases","volume":"10","author":"Oprea","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2022.106220_bib118","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12885-020-07716-1","article-title":"The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo","volume":"21","author":"Grimes","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phrs.2022.106220_bib119","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3390\/cancers11081049","article-title":"Dual actions of ketorolac in metastatic ovarian cancer","volume":"11","author":"Hudson","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2022.106220_bib120","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ajpath.2017.10.018","article-title":"The R-enantiomer of ketorolac delays mammary tumor development in mouse mammary tumor virus-polyoma middle T antigen (MMTV-PyMT) mice","volume":"188","author":"Peretti","year":"2018","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.phrs.2022.106220_bib121","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.4254\/wjh.v13.i12.2039","article-title":"Deep learning in hepatocellular carcinoma: current status and future perspectives","volume":"13","author":"Ahn","year":"2021","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.phrs.2022.106220_bib122","doi-asserted-by":"crossref","unstructured":"K.M. Wong, G.G. King, W.P. Harris, The treatment landscape of advanced hepatocellular carcinoma. Curr Oncol Rep. (2022). \u3008https:\/\/doi.org\/10.1007\/s11912-022-01247-7\u3009. Online ahead of print.","DOI":"10.1007\/s11912-022-01247-7"},{"key":"10.1016\/j.phrs.2022.106220_bib123","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1080\/15384047.2020.1809923","article-title":"Rac1 repression reverses chemoresistance by targeting tumor metabolism","volume":"21","author":"Ganapathy-Kanniappan","year":"2020","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.phrs.2022.106220_bib124","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.591623","article-title":"Identification of prognostic biomarkers and correlation with immune infiltrates in hepatocellular carcinoma based on a competing endogenous RNA Network","volume":"12","author":"Pu","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.phrs.2022.106220_bib125","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1515\/med-2021-0405","article-title":"Gene signature to predict prognostic survival of hepatocellular carcinoma","volume":"17","author":"Li","year":"2022","journal-title":"Open Med."},{"key":"10.1016\/j.phrs.2022.106220_bib126","doi-asserted-by":"crossref","first-page":"9589","DOI":"10.1007\/s13277-015-3727-1","article-title":"Specific upregulation of RHOA and RAC1 in cancer-associated fibroblasts found at primary tumor and lymph node metastatic sites in breast cancer","volume":"36","author":"Rozenchan","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.phrs.2022.106220_bib127","doi-asserted-by":"crossref","first-page":"41959","DOI":"10.18632\/oncotarget.9747","article-title":"Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects","volume":"7","author":"Neubauer","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2022.106220_bib128","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.642563","article-title":"Five-gene signature for prognosis prediction in hepatocellular carcinoma","volume":"11","author":"Su","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2022.106220_bib129","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3892\/etm.2021.10973","article-title":"Identification of potential biomarkers for diagnosis of hepatocellular carcinoma","volume":"23","author":"Liang","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.phrs.2022.106220_bib130","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1158\/1535-7163.MCT-16-0442","article-title":"Characterization of a dual Rac\/Cdc42 inhibitor MBQ-167 in metastatic cancer","volume":"16","author":"Humphries-Bickley","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2022.106220_bib131","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1158\/1535-7163.MCT-21-0348","article-title":"Efficacy of Rac and Cdc42 inhibitor MBQ-167 in triple-negative breast cancer","volume":"20","author":"Cruz-Collazo","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2022.106220_bib132","unstructured":"V. Sauzeau, G. Loirand, J. Lebreton, A. Tessier, A. Quemener, Inhibitors of Rac1 and uses thereof for treating cancers. European Patent 3412652A1 (filed 06.06.2017)."},{"key":"10.1016\/j.phrs.2022.106220_bib133","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.7150\/ijms.59930","article-title":"A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents","volume":"18","author":"Gao","year":"2021","journal-title":"Int. J. Med. Sci."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822001657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822001657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:36:50Z","timestamp":1760913410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822001657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":133,"alternative-id":["S1043661822001657"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106220","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overexpressed or hyperactivated Rac1 as a target to treat hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106220","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106220"}}